Table 1 'E': enzyme; 'I': Inhibitor. Currently, we have only applied the mass action law for implementing biochemical reaction
From: A microRNA molecular modeling extension for prediction of colorectal cancer treatment
Sirolimus treatment | CRC patient + sirolimus | CRC patient |
|---|---|---|
Molecular modeling | mTor complex II (E); Sirolimus (I) | mTor complex II (E) |
PRKCG + ATP → → → P-PRKCG + ADP | PRKCG + ATP → → → P-PRKCG + ADP | |
mTor complex II (E); Sirolimus (I) | mTor complex II (E) | |
SGK + ATP → → → P-SGK + ADP | SGK + ATP → → → P-SGK + ADP | |
mTor complex II (E); Sirolimus (I) | mTor complex II (E) | |
PRKCA + ATP → → → P-PRKCA + ADP | PRKCA + ATP → → → P-PRKCA + ADP | |
mTor complex II (E); Sirolimus (I) | mTor complex II (E) | |
AKT + ATP → → → P-AKT + ADP | AKT + ATP → → → P-AKT + ADP | |
mTor complex II (E); Sirolimus (I) | mTor complex II (E) | |
HIF1A + ATP → → → P-HIF1A + ADP | HIF1A + ATP → → → P-HIF1A + ADP | |
mTor complex II (E); Sirolimus (I) | mTor complex II (E) | |
PPARGC1 + ATP → →P-PPARGC1 + ADP | PPARGC1 + ATP → P-PPARGC1 + ADP | |
mTor complex II (E); Sirolimus (I) | mTor complex II (E) | |
EIF4EBP + ATP → → P-EIF4EBP + ADP | EIF4EBP + ATP → →P-EIF4EBP + ADP | |
mTor complex II (E); Sirolimus (I) | mTor complex II (E) | |
PPARG + ATP → → P-PPARG + ADP | PPARG + ATP → → P-PPARG + ADP | |
LY294002 treatment | CRC patient + LY294002 | CRC patient |
Molecular modeling | Enzymes; LY294002 (I) | Enzymes |
PIP2 + ATP → → → PIP3 + ADP | PIP2 + ATP → → → PIP3 + ADP |